StocksBiogen IncBIIB

BIIB

Biogen Inc

199.65 6.56 (3.40%)
Prezzi ritardati da NASDAQ, in USD Mercato chiuso
Investi
S
199.47
B
199.95
Top
Andrei Franco
𝗦𝗮𝗴𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀' 𝗳𝗶𝗿𝘀𝘁 𝗾𝘂𝗮𝗿𝘁𝗲𝗿 𝟮𝟬𝟮𝟮 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 Cash Position: As of March 31, 2022, the company had $1.6 billion in cash, cash equivalents, and marketable securities. This was down from $1.7 billion as of December 31, 2021. Sales of ZULRESSO brought in $1.6... Mostra di più Traduci
DeepNews
$BIIB (Biogen Inc) Oppenheimer Comments on Biogen Inc.’s FY2022 Earnings (NASDAQ:BIIB) Analysts at Oppenheimer decreased their FY2022 earnings per share estimates for shares of Biogen in a research report issued on Wednesday, May 4th. Oppenheimer analyst J. www.defenseworld.net/2022/05/09/oppenheimer-comments-on-biogen-inc-s-fy2022-earnings-nasdaqbiib.html Traduci
Teodor-Marian Nica
❞ Investor concerns about Fed tightening, surging interest rates, and the risk of recession have outweighed the surprising strength of 1Q earnings reports $SPX500 🤷🏻‍♂️ Things are not always as bad as they seem. Often the reaction is worse. ✔️ In a zero sum game like trading, you just need to wait... Mostra di più Traduci
Mi piace CommentaCondividi
null
.
Esquis_AS
A Dividends_income shared post www.etoro.com/people/dividends_income .⭐ 𝐒𝐈𝐌𝐏𝐋𝐘 𝐒𝐀𝐅𝐄 𝐃𝐈𝐕𝐈𝐃𝐄𝐍𝐃𝐒 𝐈𝐍𝐂𝐎𝐌𝐄 ⭐ .🎯 Mindset: confidence in our investment choices 🎯 .𝗙𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗶𝗻𝘁𝗲𝗹𝗹𝗶𝗴𝗲𝗻𝗰𝗲 I wanna share with you a new mindset, which will go a little outside the... Mostra di più Traduci
MarketUpdates
Il rapporto sugli utili di $BIIB (Biogen Inc) riferiti al T2 2022 dovrebbe essere pubblicato
28
LUG
REPORT
Il rapporto sugli utili riferiti al Biogen Inc T2 2022 dovrebbe essere pubblicato a mercati chiusi
Notifica
BIIB
BIIB
Biogen Inc
199.65
6.56
(3.40%)
Investi